Comparative study of mupirocin and sodium fucidate in the prophylaxis of exit-site infections in CAPD patients

Peritoneal Dialysis International

Volumn 23, Issue 6, 2003, Pages 593-595

  Danguilan, Romina A ^a   Evangelista, Liezl P ^a   Abrenica, Mildred S ^a   Rondilla, Stella Marie S ^a  

^a National Kidney Transplant Institute   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

2 PROPANOL; FUSIDATE SODIUM; OFLOXACIN; POVIDONE IODINE; PSEUDOMONIC ACID; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CATHETER INFECTION; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORBIDITY; OINTMENT; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; WOUND DRESSING;

EID: 0348111298     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080302300614     Document Type: Article

References (10)

1. Piraino B, Bernardini J, Sorkin M. The influence of peritoneal catheter exit site infections on peritonitis, tunnel infections and catheter loss in patients on CAPD. Am J Kidney Dis 1986; 8:436-40.
2. Zimmerman SW, O'Brien M, Wiedenhoeft FA, Johnson C. Staphylococcus aureus peritoneal catheter related infections: a cause of catheter loss and peritonitis. Perit Dial Int 1988; 8:191-4.
3. Thodis E, Bhaskaran S, Pasadakis P, Bargman J, Vas S, Oreopoulos DG. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18:261-70.
4. Bernardini B, Piraino J, Holly J, Johnston J, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27:695-700.
5. Thodis E, Pasadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemesis V. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis. Adv Perit Dial 2000; 16:257-61.
6. Annigeri R, Conly J, Vas SI, Dedier H, Prakashan KP, Bargman JM, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21:544-58.
7. Rosales M, Perez-Fontan M, Rodriguez-Carmona A, Garcia-Falcon T. Increasing resistance to mupirocin of Staphylococcus aureus strains isolated from peritoneal dialysis patients and their partners: long term study [Abstract]. Perit Dial Int 2001; 21(Suppl 2):S128.
8. Twardowski W, Prowant BF. Classification of normal and diseased exit sites. Perit Dial Int 1996; 16(Suppl 3): S32-50.
9. Vas S, Conly J, Bargman JM, Oreopoulos DG. Resistance to mupirocin: no indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit site infections in peritoneal dialysis patients. Perit Dial Int 1999; 19:313-14.
10. Sesso R, Parisio K, Dalboni A, Rabelo T, Barbosa D, Cendoro M, et al. Effect of sodium fucidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1994; 41: 370-6.